Sickle cell disease

19 trials 7 recruiting MedDRA PT
19 Registered trials
7 Recruiting
13 Unique sponsors
12 Unique IMPs
14 Commercial trials
Drug classes (ATC)
— ATC code not specified 16
L Oncology (ATC L) 1
B Haematology (ATC B) 1
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 8 substances
Monoclonal antibody (immune) 1 substance
Monoclonal antibody (immune, humanized) 1 substance
BTK inhibitor 1 substance
Supportive / diluent 1 substance
Phase III: 6 Phase II/III: 2 Phase II: 4 Phase I/II: 1 Phase IV: 2 Phase I: 1 Phase I (Other): 1 Phase I (First in Human): 2

Filter these 19 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 19 trials

Phase III

6 trials
  • Genetix Biotherapeutics Inc. Commercial
    LOVOTIBEGLOGENE AUTOTEMCEL
    2024-513901-30-00 1 country 2020 n=3
    Recruiting
  • Novartis Pharma AG Commercial
    CRIZANLIZUMAB
    2023-508689-14-00 5 countries 2019 n=31
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    RILZABRUTINIB
    2024-518645-17-00 7 countries 2025 n=58 Orphan
    Recruiting
  • Assistance Publique Hopitaux De Paris Academic
    SODIUM CHLORIDE
    2023-505109-17-00 1 country 2025 n=130
    Recruiting
  • Assistance Publique Hopitaux De Paris Academic
    METHOXYFLURANE 99.9%
    2024-518043-38-00 1 country n=198
    Not authorised
  • Centre Hospitalier Universitaire De Nantes Academic
    IMP not specified
    2024-518437-28-00 1 country n=104
    Pending

Phase II/III

2 trials
  • Global Blood Therapeutics Inc. Commercial
    (S)-2-HYDROXY-6-((4-(2-(2-HYDROXYETHYL)NICOTINOYL)MORPHOLIN-3-YL)METHOXY)BENZALDEHYDE
    2023-508766-14-00 2 countries n=20
    Suspended
  • Novo Nordisk A/S Commercial
    ETAVOPIVAT
    2024-511535-97-00 5 countries 2021 n=94 Orphan
    Ended

Phase II

4 trials
  • Agios Pharmaceuticals Inc. Commercial
    MITAPIVAT
    2023-510289-28-00 2 countries n=17
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2022-502542-28-00 4 countries 2021 n=15
    Ended
  • Julius Clinical Research B.V. Commercial
    MITAPIVAT
    2024-515569-32-00 1 country 2020 n=10
    Ended
  • Theravia Commercial
    HYDROXYCARBAMIDE
    2024-513750-30-00 1 country 2026 n=50
    Recruiting

Phase I/II

1 trial
  • Novo Nordisk A/S Commercial
    ETAVOPIVAT
    2024-519881-32-00 1 country n=9 Orphan
    Pending

Phase IV

2 trials
  • Novartis Pharma AG Commercial
    CRIZANLIZUMAB
    2024-510734-41-00 5 countries 2021 n=22
    Ended
  • CHU Saint Pierre Academic
    IMP not specified
    2025-523777-41-01 1 country n=40
    Pending

Phase I

1 trial
  • Novo Nordisk A/S Commercial
    IMP not specified
    2023-504582-22-00 1 country n=48
    Not authorised

Phase I (Other)

1 trial
  • F. Hoffmann-La Roche AG Commercial
    CROVALIMAB
    2022-502546-26-00 4 countries 2023 n=16
    Ended

Phase I (First in Human)

2 trials
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    BMS-986470
    2023-510283-12-00 1 country 2025 n=6
    Recruiting
  • Assistance Publique Hopitaux De Paris Academic
    DREAM01
    2025-521257-17-00 1 country 2026 n=13
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novo Nordisk A/S Commercial 3 Phase I, Phase II/III, Phase I/II 0
Assistance Publique Hopitaux De Paris Academic 3 Phase III, Phase I (First in Human) 2
F. Hoffmann-La Roche AG Commercial 2 Phase I (Other), Phase II 0
Novartis Pharma AG Commercial 2 Phase III, Phase IV 1
Global Blood Therapeutics Inc. Commercial 1 Phase II/III 0
Agios Pharmaceuticals Inc. Commercial 1 Phase II 0
Julius Clinical Research B.V. Commercial 1 Phase II 0
Theravia Commercial 1 Phase II 1
Genetix Biotherapeutics Inc. Commercial 1 Phase III 1
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase III 1
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase I (First in Human) 1
Centre Hospitalier Universitaire De Nantes Academic 1 Phase III 0
CHU Saint Pierre Academic 1 Phase IV 0
New trials by year
2019
1
2020
2
2021
3
2023
1
2025
3
2026
2
← All indication landscapes